Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bedoradrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 15/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bedoradrine SCHEMBL29379919 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL7586092 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3828783 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3828780 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3694818 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3694819 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL678131 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL29385851 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL1261689 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| SCHEMBL7585377 | 0.94 | ADRB1 (0.64) | ADRB1ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066513-A1 | METHODS FOR COMPOSITIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | MEDICINOVA, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066513-A1 | METHODS FOR COMPOSITIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | MEDICINOVA, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8518995-B2 | Methods and compositions for the treatment of irritable bowel syndrome | MEDICINOVA, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518995-B2 | Methods and compositions for the treatment of irritable bowel syndrome | MEDICINOVA, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120035265-A1 | COMPOSITIONS, METHODS, AND DEVICES FOR THE TREATMENT OF DYSMENORRHEA | MEDICINOVA, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120035265-A1 | COMPOSITIONS, METHODS, AND DEVICES FOR THE TREATMENT OF DYSMENORRHEA | MEDICINOVA, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20110319490-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | MEDICINOVA, INC. | 2011-12-29 | — | — | US | disclosed |
| US-20110319490-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | MEDICINOVA, INC. | 2011-12-29 | — | — | US | disclosed |
| WO-2011126967-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | MEDICINOVA, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011112499-A1 | COMPOSITIONS, METHODS, AND DEVICES FOR THE TREATMENT OF DYSMENORRHEA | MEDICINOVA, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319490-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, FABP2 | ADRB2 140/4885ADRB1 194/4885ADRB3 124/4885 |
| US-20120035265-A1 | COMPOSITIONS, METHODS, AND DEVICES FOR THE TREATMENT OF DYSMENORRHEA | CYP19A1, SHBG, HSD17B11 | ADRB2 658/4885ADRB1 1119/4885ADRB3 746/4885 |
| US-20140066513-A1 | METHODS FOR COMPOSITIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, FABP2, SLC10A2 | ADRB2 163/4885ADRB1 235/4885ADRB3 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.